Latest1 information on COVID-19
©2022 Stanford Medicine
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Not Recruiting
Trial ID: NCT00186394
Purpose
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of
NHL.
Official Title
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
Stanford Investigator(s)
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Eligibility
Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma
Age: >18 and <61 years of age
Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum
transaminases >2.5X normal values
Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min
Diseases other than non-Hodgkin's lymphoma
Prior bone marrow transplant procedure
Severe psychological or medical illness
Intervention(s):
procedure: ablative allogeneic hematopoietic cell transplantation
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822